Radium Incorporated

About Radium Incorporated

Radium Incorporated sits in Other / Uncategorized, a segment Bracken sees as structurally important to the radiopharma value chain.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• Reuters Health · 2026-05-24
  Radium Incorporated expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-10-03
  Radium Incorporated announces Phase II readout for lead theranostic candidate
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• FierceBiotech · 2026-11-26
  Radium Incorporated appoints new Chief Medical Officer ahead of pivotal trial
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• BioPharma Reporter · 2026-08-05
  Radium Incorporated signs supply agreement to support late-stage trials
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Imaging Wire · 2026-05-12
  Radium Incorporated closes Series C round to scale radiopharma manufacturing
  Coverage notes the company's growing footprint in the radioligand therapy space.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.